Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 AE 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N ¼ 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N ¼ 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N ¼ 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 AE 37 months.
Introduction
The incidence of AF is increasing in Japan as the population ages. AF not only decreases the quality of life, but also may sometimes be associated with thromboembolism or heart failure, 1, 2) and it worsens the cardiovascular prognosis of patients with left ventricular dysfunction. 3) The Japanese Circulation Society (JCS) Guidelines 4) that recommends pharmacologic therapy to prevent embolism in patients with nonvalvular AF should be selected on the basis of risk assessment.
However, in clinical practice, thromboembolism occasionally develops in non-elderly patients with nonvalvular AF. Japanese AF patients younger than 60 years of age have been reported to suffer a death rate from ischemic stroke 2 to 3 times higher in comparison to patients who do not have AF and the cardiovascular prognosis also tends to be more serious in AF patients. 5) Therefore, the prevention of thromboembolism in non-elderly AF patients who are generally believed to be at low risk is important, but it remains uncertain whether the antithrombotic therapy recommended by the JCS Guidelines provides a valid strategy.
In the present study, we retrospectively examined the cardiovascular prognosis of antithrombotic therapy according to the JCS Guidelines in low-risk patients with NVPAF.
Methods

Patients and definitions
Among 342 patients with paroxysmal AF in whom 12-lead and Holter electrocardiogram (ECG) confirmed the presence of AF consistent with their symptoms, 150 patients (117 men and 33 women with a mean age of 68 AE 12 years) who had no risk factors for thromboembolism that did not show the valvular heart disease by transthoracic echocardiography were enrolled. All patients attended our hospital at intervals of 2-4 weeks and presented for the treatment of symptoms that interfered with their daily activities. The study was conducted from June 1993 to August 2005, with a mean follow-up period of 56 AE 37 months (range: 12-127 months).
All patients underwent history hearing, chest radiography, exercise testing and echocardiography. In addition, pulmonary function tests, chest computed tomography and cardiac catheterization were performed when it was considered to be necessary by the physician. Cerebral thromboembolism was diagnosed on the basis of symptoms and the detection of an infarct ! 3 mm in size by computed tomography or magnetic resonance imaging of the brain. Hypertension was defined as a systolic blood pressure of ! 140 mmHg or a diastolic blood pressure of ! 90 mmHg on casual clinic monitoring. 6) Paroxysmal AF was defined as the spontaneous onset and termination of one or more episodes of tachycardia within 2-7 days, 7) while progression to chronic AF was defined as the absence of confirmation of sinus rhythm during a 6-month period despite treatment with aggressive antiarrhythmic drug therapy. In this study, we determined the CHADS2 score 8) and evaluated the risk. However, we excluded age in this study, but included coronary disease. Therefore, the risk factors for thromboembolism were a previous transient ischemic attack or cerebral infarction, hypertension, diabetes mellitus, coronary artery disease and recent heart failure. 4) In addition, major bleeding was defined as either a hemorrhage which required a transfusion or an intracranial hemorrhage.
Patients were excluded from the study if they had heart failure, serious bradyarrhythmias (sick sinus syndrome, atrioventricular block, or intraventricular conduction disturbance), or hepatic or renal dysfunction. Women who might be pregnant and patients were receiving -blockers or T-type calcium channel blockers were also excluded.
Protocol for antiarrhythmic drug therapy
All patients received antiarrhythmic drug therapy for maintenance of sinus rhythm (rhythm control therapy). Patients with a left ventricular ejection fraction of ! 40% on transthoracic echocardiography were assigned by the sealed envelop method to receive disopyramide (300 mg/day), aprindine (60 mg/day), or cibenzoline (300 mg/day) as the first-line agent after spontaneous or pharmacologic/ electrical defibrillation. Patients who had recurrence of AF were assigned by the sealed envelope method to receive pilsicainide (150 mg/day), flecainide (150 mg/day), or bepridil (150 mg/day) as the second-line agent. Those who had repeated recurrence of AF were treated with amiodarone (200 mg/ day) or a different class I antiarrhythmic drug as the third-line agent. On the other hand, patients with a left ventricular ejection fraction of < 40% on transthoracic echocardiography were assigned by the sealed envelope method to receive aprindine (60 mg/ day) or bepridil (150 mg/day) as the first or secondline agent after spontaneous or pharmacologic/ electrical defibrillation. Patients who were unresponsive to these two drugs and had recurrent AF were given amiodarone (200 mg/day) as the third-line agent.
The details of the preventive effect on recurrence of AF achieved with these protocols have already been reported. 9) In all patients, we assessed symptoms and recorded a standard 12-lead ECG after they started the assigned antiarrhythmic drugs or 2-4 weeks after changing therapy and performed simplified ambulatory ECG monitoring at each hospital visit to assess the presence or absence of sinus rhythm. If the attending physician considered it necessary, a Holter ECG recording was obtained every three months to identify the presence or absence of AF. At the time of changing antiarrhythmic drugs, each patient whose ECG confirmed the maintenance of sinus rhythm underwent measurement of the plasma atrial natriuretic peptide level using blood obtained from an upper limb vein while the subject was at rest in the supine position. On the other hand, patients in whom AF became chronic despite antiarrhythmic therapy were treated orally with -blockers, calcium antagonists, or digitalis for ventricular rate control.
Protocol for antithrombotic therapy Antithrombotic therapy was provided at the discretion of the attending physician before the JCS Guidelines were released in November 2001. Thereafter, antithrombotic therapy was mainly selected in accordance with the JCS Guidelines. The dose of aspirin was set at 81-100 mg/day and the dose of warfarin was set to maintain an international normalized ratio (INR) of 1.6-2.6. The INR range during follow-up was 1.3-3.1 (mean: 1.9).
In accordance with the recommendations of the JCS Guidelines, the patients were classified into three age groups: < 60 years of age (group I, N ¼ 58); 60-75 years of age (group II, N ¼ 68); and > 75 years of age (group III, N ¼ 24). The clinical characteristics of the patients in each group were compared after stratification according to the presence or absence of antithrombotic therapy. Thereafter, the annual rate of thromboembolic events stratified according to the presence or absence of antithrombotic therapy and the incidence of complications due to antithrombotic therapy were compared among the three groups.
Statistical analysis
Results are expressed as the mean AE standard deviation. The One-way ANOVA test was used for comparisons of the continuous variables among each group, receiving antithrombotic therapy and not receiving antithrombotic one. The chi square test was used for comparisons of the proportions among the age groups. Differences were considered to be significant at the level of P < 0:05 for all analyses.
Results
Clinical profile 1. Patients under age 60 (group I; Table 1) The left atrial diameter measured by transthoracic echocardiography was significantly greater in the patients receiving antithrombotic therapy (group A, N ¼ 18) than in those not receiving antithrombotic therapy (group B, N ¼ 40; P < 0:05). No other significant difference were recognized between groups A and B. The underlying heart disease included sick sinus syndrome in two patients, hypertrophic cardiomyopathy in one, myocarditis in one and an atrial-septal defect in one.
2. Patients between ages 60 and 75 (group II; The left atrial diameter on transthoracic echocardiography, the prevalence of underlying heart disease and the percentage of patients on oral reninangiotensin-aldosterone system (RAAS) inhibitors were all significantly greater for the patients receiving antithrombotic therapy (group A, N ¼ 36) than for those without antithrombotic therapy (group B, N ¼ 32; P < 0:05), but no other significant differences were recognized. The underlying heart diseases included dilated cardiomyopathy in six patients, sick sinus syndrome in four patients, hypertrophic cardiomyopathy in three, atrial septal defect in two, myocarditis in one and syndrome X in one.
3. Patients more than age 75 (group III; Table 3 )
The left atrial diameter on transthoracic echocardiography, the duration of disease and the percentage of patients on oral RAAS inhibitors were significantly greater for patients receiving antithrombotic therapy (group A, N ¼ 7) than for those without antithrombotic therapy (group B, N ¼ 17; P < 0:05), but no other significant differences were recognized. The underlying heart disease was hypertrophic cardiomyopathy in three patients, dilated cardiomyopathy in two, sick sinus syndrome in one, and syndrome X in one.
4. All patients ( Table 4) The proportions of male patients and patients with organic heart disease were significantly greater for group I than for groups II and III (P < 0:05). The percentages patients who habitually smoked or took alcohol were significantly greater for group I than for group III (P < 0:01, P < 0:05). On the other hand, the left atrial diameter (LAD) was significantly greater in group III than in group I (P < 0:05). The percentage of hyperlipidemia was significantly greater for group III than for groups I and II (P < 0:01). Otherwise, there were no significant differences among the three groups.
Incidence and annual rate of thromboembolism in patients with paroxysmal AF ( Table 5) The overall annual rate of thromboembolism was significantly higher in group III than in groups I and The annual rate of thromboembolism in patients receiving aspirin therapy was significantly higher in group III than in groups I and II (P < 0:05). However, for patients treated with warfarin, there were no significant differences in the rate among the three groups. The INR before thromboembolism occurred in one patient on warfarin therapy was 1.4.
Incidence and annual rate of major bleeding in patients with paroxysmal AF on antithrombotic therapy ( Table 6) The annual rate of major bleeding complications for all patients was 0.9%, and there were no significant differences among the age groups or between the aspirin and warfarin groups.
Discussion
Incidence and annual rate of thromboembolism Large-scale controlled trials performed in Europe and North America have shown that the annual rate of thromboembolism in patients with nonvalvular AF is 3.0-6.3%. [10] [11] [12] [13] [14] [15] This annual rate is reduced to 3.4-4.7% by treatment with aspirin and to 0.4-2.5% by warfarin therapy. The reported variation in the annual rate of thromboembolism may be due to differences in the level of risk among the subjects of the study, as well as differences in the length of follow-up. In Japan, the annual rate of thromboembolism in patients with nonvalvular AF has been reported to be 2.2-4.5%. [16] [17] [18] Similarly, the annual rate is reduced to 1.4-4.4% by aspirin therapy, and to 0.7-1.5% by treatment with warfarin. On the other hand, a meta-analysis of large-scale controlled trials from Europe and North America has shown that risk factor-free patients, younger than 65 years old, have a low annual thromboembolism rate of 1.0%. 1) In contrast, an analysis of 20,000 patients attending cardiovascular departments in Japan showed that the annual rate for those under age 60 with nonvalvular AF was a relatively high 1.8%, 19) which was similar to the current results. Furthermore, a recent Japanese epidemiologic study indicated that AF increases the relative risk of death due to ischemic stroke 14.7fold and increases the risk of the cardiovascular death 9.6-fold in patients under 65 years old. 20) In the present study of patients who had nonvalvular AF without thromboembolic risk factors, three patients under 60 years old were observed to have a thromboembolism and none of them were on antithrombotic therapy (7.5%). In this study, the annual rate of thromboembolism for nonvalvular AF patients without thromboembolic risk factors was 2.4%.
Adverse effects of antithrombotic therapy
A large-scale controlled Japanese trial evaluating the preventive effect of aspirin on symptomatic ischemic stroke in patients with nonvalvular AF (Japan Atrial fibrillation and Stroke Trial [JAST study], mean follow-up 2.1 years) 21) revealed that the rate of serious bleeding was about 4 times higher than in large-scale European and North American trials. In the present study, the patients were followed for an average of 4.7 years and the annual rate of serious bleeding complications associated with aspirin therapy was 1.3%, which was slightly higher than that due to warfarin. On the other hand, a randomized controlled Japanese study of warfarin therapy for secondary prevention of ischemic stroke in AF patients showed that anticoagulation with an INR between 1.5 and 2.1 was able to prevent recurrence without intracranial hemorrhage, on the other hand, patients with an INR between 2.2 and 2.7 had an increased frequency of intracranial hemorrhage. 22) In the present study, low-dose warfarin therapy was performed with a target INR of 1.6-2.6 and the annual rate of serious bleeding complications was relatively low at 0.6%. These results suggest that Japanese patients did not required the same level of the anticoagulant therapy as those of Western countries considering that Japanese patients are prone to bleeding complications. Therefore, a target INR between 1.6 and 2.6 was considered reasonable for keeping the rate of serious bleeding complications low during warfarin therapy. Therefore attention should be paid to prevent bleeding complications during aspirin-based and warfarin-based antithrombotic therapy, especially in older patients.
Limitations
Some limitations of the present study should be mentioned. First, since all the subjects were on antiarrhythmic therapy for maintenance of sinus rhythm, it was impossible to evaluate the effect of antithrombotic therapy in patients treated with rate control therapy. The incidence of thromboembolism among patients with paroxysmal AF is dependent on their response to antiarrhythmic drug therapy. 8) In a large-scale controlled North American trial (The Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] study), sinus rhythm was maintained by rate control therapy in a relatively high 35% of the subjects. 23) In other words, the outcome for patients in whom sinus rhythm was maintained may not have been strongly influenced by the effect of antithrombotic therapy. In this study, we did not include duration and frequency of the paroxysmal AF. It is therefore considered that further study will be necessary in the future. Second, the present study was retrospective and observational in design with some bias in patient characteristics. Among patients older than age 60, the use of oral RAAS inhibitors was significantly more common for those receiving antithrombotic therapy than for those without it. A large-scale controlled North American trial recently indicated that RAAS inhibitor therapy reduces the occurrence of ischemic stroke. 24) Therefore, in the present study there is a possibility that the combination therapy of the RAAS inhibitor may influence the annual rate of ischemic stroke. Third, this study overlaps the period both before and after the guidelines were established. Therefore, the choice of the antithrombotic therapy before the guidelines may have been affected by a drug selection bias of the attending physician. Finally, the patient population investigated in this study was relatively small. Therefore, the one case has a large influence on the overall results. As a result, it is difficult to make any definitive conclusions based on the findings of this study. The validity of the JCS Guidelines should therefore be assessed by a multicenter prospective study in the future. In addition, because of the small number of such cases, we did not compare the groups which took antithrombic therapy with the groups which did not. Therefore it is thought that further examinations are necessary.
Conclusions
The JCS recommendations concerning antithrombotic therapy for nonvalvular AF appeared to be valid. To prevent thromboembolism in low-risk patients on antiarrhythmic (rhythm control) therapy, it may be advisable to use warfarin rather than aspirin. However, this study was only conducted at our institution, and there was a small number of cases. Therefore, futher investigations with a larger number of patients and many institutions will be necessary in the future. In addition, because there are many patients younger than age 60 associated with ischemic stroke, further studies might also be required to clarify the validity of the Japanese guidelines in the management of younger patients (under age 60) with NVPAF.
